CFGI’s Capital Markets team supported Applied Therapeutics (Nasdaq: APLT) with its follow-on public offering of 3,152,712 shares of its common stock, including the exercise in full of the underwriters’ option to purchase 411,223 additional shares of common stock.
The offering was priced at $45.50 per share, resulting in aggregate gross proceeds of approximately $143.4 million, before deducting underwriting discounts, commissions and estimated offering expenses. The offering closed on January 28, 2020.
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need.
The CFGI team was led by Kelly Provost (Capital Markets) and Steve Ortega (Consulting).
For further information on the offering, please read Applied Therapeutics’ press release.